Skip to main content

Table 1 Baseline patient characteristics

From: Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

  Exposed patients (n = 75) Non-exposed patients (n = 150)  
Gender (female) 18 (24%) 38 (25%) *
Mean age (years) 44 46 *
Weight (kg) 70 72 *
Mechanism of transmission *
Homosexual 18 (25%) 37 (25%) *
IVDU 29 (39%) 52 (35%) *
Heterosexual 19 (25%) 48 (32%) *
Unknown 7 (9%) 12 (8%) *
Concomitant pathologies   *
AIDS 18 (24%) 46 (30%) *
HCV 31 (40%) 56 (39%) *
Psychiatric history 17 (23%) 27 (18%) *
Methadone consumption 5 (6%) 22 (14%) *
Use of psychopharmaceuticals 14 (19%) 19 (13%) *
FDCs    *
AtriplaTM 36 (48%) 72 (48%) *
TruvadaTM 24 (32%) 48 (32%) *
KivexaTM 7 (9%) 16 (11%) *
CombivirTM 6 (8%) 14 (9%) *
TrizivirTM 2 (3%) 0 (0%) *
NNRTI 15 (20%) 28 (19%) *
PI 22 (29%) 54 (36%) *
Integrase 0 (0%) 3 (2%) *
Exposure time to FDCs (months) 27 (range: 1–121) 24 (range: 3–98) *
Exposure time to efavirenz (months) 50 (range: 129–1) 61 (range: 126–3) *
Viral load > 50 copies/mL at visit −1 12 of 74 (16.2%) 8 of 149 (5.4%) (OR: 3.4; 95%CI: 1.3-8.8; p = 0.02)
Viral load > 50 copies/mL at baseline visit 10 of 74 (13.5%) 10 of 146 (6.8%) *
CD4 at first visit (cells/μL) 573 (range: 41–1527) 542 (range: 92–1481) *
  1. IVDU: intravenous drug user; AIDS: acquired immunodeficiency syndrome; HCV: hepatitis C virus; FDCs: fixed-dose antiretroviral combinations; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; CD4: CD4+ lymphocytes; OR: odds ratio; 95%CI: confidence intervals at the 95% level.
  2. *No statistically significant differences.